Deals In Depth: October 2015
Executive Summary
BMS replaced and signed a new deal with Five Prime Therapeutics in immuno-oncology; there was more consolidation in the pharma services industry with Walgreens' $17.2 billion acquisition of Rite Aid. Biopharma financing in October was down from the previous month to $2.1 billion; device fundraising also decreased, to $468 million.
You may also be interested in...
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.